

# Retinal Diseases

---

*Ala Moshiri M.D. Ph.D.*  
*U.C. Davis Eye Center*

# Financial Disclosures

**NONE**


# Overview

- **Background Information**
- **Retinal Vascular Disease**
- **Age-Related Macular Degeneration**
- **Diabetic Retinopathy**
- **Questions from the Audience**


# Overview

- **Background Information**
- **Retinal Vascular Disease**
- **Age-Related Macular Degeneration**
- **Diabetic Retinopathy**
- **Questions from the Audience**


- The eye can only perceive a small portion of the spectrum of electromagnetic waves




# Sectional Anatomy of the Eye



# The Organization of the Retina



(b)



(c)

# Overview


- Background Information
- **Retinal Vascular Disease**
- Age-Related Macular Degeneration
- Diabetic Retinopathy
- Questions from the Audience



# Case 1

- **76 yo man notices his right eye is blurry and will not improve.**
- **He can barely distinguish the fingers on his own hand, even with glasses.**
- **He does not have pain.**

# Central Retinal Artery Occlusion






# Case 2

- **68 yo woman notices her left eye does not see clearly today.**
- **She cannot read or even recognize faces with the left eye, even with glasses.**
- **She does not have pain.**

# Central Retinal Vein Occlusion





# Overview

- **Background Information**
- **Retinal Vascular Disease**
- **Age-Related Macular Degeneration**
- **Diabetic Retinopathy**
- **Questions from the Audience**

# Overview

➤ **Dry AMD**

➤ **Wet AMD**



# Overview

- **Dry AMD**
- **Wet AMD**



# Vitamins for Dry AMD

## ➤ AREDS 2

- Vitamin C - 500 mg
- Vitamin E - 400 IU
- Zinc - 80 mg
- Copper - 2 mg
- Lutein - 10 mg
- Zeaxanthin - 2 mg



# Case 3


- A 72 yo patient with “dry AMD” has been noticing bending and distortion in the right eye of things she knows to be straight. Letters seem smaller out of this eye than the other eye.



# Overview

- **Dry AMD**
- **Wet AMD**





# Overview

- **Background Information**
- **Retinal Vascular Disease**
- **Age-Related Macular Degeneration**
- **Diabetic Retinopathy**
- **Questions from the Audience**

# Diabetic Retinopathy


---

- Diabetic retinopathy is the most common cause of new cases of blindness among adults 20-74 years of age.
- Each year, about 24,000 people lose their sight because of diabetes.
- During the first two decades of disease, nearly all patients have retinopathy

# Retinopathy Screening

---


- **Type 1 diabetes - screen within 5 years of diagnosis**
- **Type 2 diabetes - screen at time of diagnosis**
- **Pregnancy - women with preexisting diabetes should be screened prior to conception and during first trimester**
- **Examination Methods – Dilated ophthalmoscopy**





# Natural History of Diabetic Retinopathy

---



- **Mild nonproliferative diabetic retinopathy (NPDR)**
- **Moderate NPDR**
- **Severe NPDR**
- **Very Severe NPDR**
- **Proliferative diabetic retinopathy (PDR)**


# Mild/Moderate NPDR

---



# Severe NPDR

---



lipid exudate    intraretinal hemorrhages

(From Kaiser PK, Friedman NJ, Pineda R II: *Massachusetts Eye and Ear Infirmary Illustrated Manual of Ophthalmology*, 2nd ed, Philadelphia, Saunders, 2004.)



Elsevier items and derived items © 2005 by Elsevier Inc.

# PDR

---

- **Proliferative Diabetic Retinopathy**
  - **Neovascularization**
    - at the optic disk (NVD)
    - elsewhere in the retina (NVE)
  - **Vitreous hemorrhage**
  - **Retinal traction, tears, and detachment**


# Proliferative retinopathy



Pre-retinal haemorrhage



Laser burn scars



neovascularization

capillary nonperfusion


(From Kaiser PK, Friedman NJ, Pineda R II: *Massachusetts Eye and Ear Infirmary Illustrated Manual of Ophthalmology*, 2nd ed, Philadelphia, Saunders, 2004.)


Elsevier items and derived items © 2005 by Elsevier Inc.

# TREATMENT

---


- **LASER: Light Amplification by the Stimulated Emission of Radiation**
  - Focal
  - Grid
  - Panretinal photocoagulation







# PDR Retinal Detachment



# PDR Retinal Detachment



# Diabetic Macular Edema

---






Hard  
exudate




# Normal OCT

Macular Thickness: Macular Cube 512x128


OD  OS




Overlay: ILM - RPE Transparency: 50 %



ILM - RPE



ILM



RPE


	Central Subfield Thickness um	Volume mm3	Average Thickness um
ILM - RPE	235	10.1	279

Comments


Physician's Signature

SW Ver: 2.0.1.3  
Copyright 2007  
Carl Zeiss Meditec, Inc.  
All Rights Reserved  
Page 1 of 1


# Diabetic Macular Edema OCT




# DME laser treatment



# DME laser treatment








# Randomization

Randomly Assigned Eyes  
(one per participant):

N = 660



# Ocular Baseline Characteristics

	<b>Aflibercept (N = 224)</b>	<b>Bevacizumab (N = 218)</b>	<b>Ranibizumab (N = 218)</b>
<b>Mean visual acuity letter score (~Snellen Equivalent)</b>	<b>69 (20/40)</b>	<b>69 (20/40)</b>	<b>68 (20/50)</b>
<b>Mean OCT CST (<math>\mu\text{m}</math>)</b>	<b>387</b>	<b>376</b>	<b>390</b>
<b>Any Prior Focal/Grid Laser</b>	<b>36%</b>	<b>39%</b>	<b>37%</b>
<b>Any Prior Treatment with anti-VEGF</b>	<b>11%</b>	<b>14%</b>	<b>13%</b>
<b>Phakic</b>	<b>74%</b>	<b>73%</b>	<b>79%</b>


# DME Treatment Through 1 Year: anti-VEGF and Laser

	Aflibercept N = 208	Bevacizumab N = 206	Ranibizumab N = 206	P- Value
<b># of Injections (Max = 13)</b>				
<b>Mean</b>	<b>9.2</b>	<b>9.7</b>	<b>9.4</b>	
<b>Median (25<sup>th</sup>, 75<sup>th</sup> percentile)</b>	<b>9 (8, 11)</b>	<b>10 (8, 12)</b>	<b>10 (8, 11)</b>	<b>0.045<sup>†</sup></b>
<b>At least one focal/grid laser</b>	<b>37%</b>	<b>56%</b>	<b>46%</b>	<b>&lt;0.001<sup>‡</sup></b>

<sup>†</sup>Global (overall 3 group comparison) P-value. Pairwise comparisons (adjusted for multiple comparisons): aflibercept-bevacizumab: P = 0.045, aflibercept-ranibizumab: P = 0.19, bevacizumab-ranibizumab: P = 0.22.

<sup>‡</sup>Global (overall 3 group comparison) P-value. Pairwise comparisons (adjusted for multiple comparisons): aflibercept-bevacizumab: P < 0.001, aflibercept-ranibizumab: P = 0.058, bevacizumab-ranibizumab: P = 0.061.

# Mean Change in Visual Acuity Letter Score, Full Cohort




\* P-values adjusted for baseline visual acuity and multiple comparisons


# Subgroup Analysis

## Baseline Best-corrected Visual Acuity

20/32-20/40



20/50 or worse



 Aflibercept

 Bevacizumab

 Ranibizumab

# Conclusion

- All three anti-VEGF agents are effective treatments for DME
- When initial visual acuity loss is mild, on average there is little difference in visual acuity at 1-year.
- At worse levels of initial visual acuity aflibercept is more effective at improving vision.

# End-stage diabetic eye disease



## ➤ PHTHISIS

Shrunken, soft eye  
with

opaque vascularised  
cornea and no visual  
potential

# Prevention of Diabetic Retinopathy Associated Vision Loss

---

- Intensive glycemic control
- blood pressure control  
( $<130/80$  mmHg)
- Annual dilated eye  
examinations



# Overview

- **Background Information**
- **Retinal Vascular Disease**
- **Age-Related Macular Degeneration**
- **Diabetic Retinopathy**
- **Questions from the Audience**